Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Compuestos heterocíclicos derivados potentes en neuropatía traumática y agentes antiinflamatorios en enfermedades asociadas a inflamación neurogénica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOHU20160426001
Publicado:
20/05/2016
Caducidad:
20/05/2017
Resumen:
Una universidad húngara ha desarrollado compuestos heterocíclicos derivados potentes con antagonista del receptor de somatostatina 1 y 4 y varios tipos de efectos inhibidores de quinasa. Estos compuestos han demostrado ser eficaces contra inflamaciones neurogénicas y dolor neuropático en roedores y han sido identificados como nuevos candidatos a medicamentos para la prevención y tratamiento de la inflamación neuropática aguda o hiperalgesia neuropática. La universidad busca socios con el fin de establecer acuerdos de investigación, desarrollo conjunto y licencia.

Details

Tittle:
Potent heterocyclic derivative compounds analgesics in traumatic neuropathy and anti-inflammatory agents in neurogenic inflammation releated diseases
Summary:
A Hungarian university developed potent heterocyclic derivative compounds with somatostatin receptor 4 and somatostatin receptor 1 antagonist and several type of kinase inhibiting effects, proved to be effective against neurogenic inflammations and neuropathic pain in rodents.
Identified as new drug candidates for the prevention/treatment of acute neurogenic inflammation and/or neuropathic hyperalgesia. Partners for research cooperation, joint development and out-licensing are welcome.
Description:
This is an offer of a Hungarian university dealing with research in the field of neurogenic inflammation. The neurogenic and neuropathic pain derives from the chemical reaction of the nerve and/or mechanical injuries of neuropeptide sensors. Neurogenic inflammation is an important element of several diseases such as rheumatoid arthritis, allergic contact dermatitis, psoriasis, asthma and inflammatory bowel diseases.

Sensory neuropeptides (e.g. substance P: SP, neurokinin A: NKA, calcitonin gene-related peptide: CGRP) are released from the activated nerves which cause vasodilatation, leakage of plasma protein, and abnormal innervation in the field of immune cells. These peptides, as well as the immune-cell derived mediators, sensitize the nerve endings which causes pain.

Neuropathic pain induced by peripheral nerve damage in cases of herpes zoster infection, HIV, nutritional deficiencies, toxins, malignancies, immune-mediated disorders and physical trauma to a nerve trunk, affects great number of patients, it is related to peripheral sensitization of the nerve endings and central sensitization of the secondary sensory neurones in the spinal cord.

The neurogenic inflammatory component of the above mentioned diseases is not eliminated by the conventional anti- inflammatory drugs (COX inhibitors), and glucocorticoids are only moderately effective and exert many severe side-effects which limit their clinical application.

Neuropathic pain is resistant to COX inhibitors or opioid analgesics, only certain anti-depressants or anti-epileptics (adjuvant analgesics) are moderately effective in some cases, but not in case of nerve trauma-evoked neuropathy.

Therefore, it is particularly important to identify novel therapeutical targets and mechanisms in such conditions. Targeting the peptidergic sensory nerves and inhibiting their pathological activation and the release of pro-inflammatory sensory neuropeptide, might be a novel pathway to inhibit neurogenic inflammation and neuropathic pain. The university seeks research cooperation, partners for common development and out-licensing partners from all countries.
Advantages and Innovations:
Identification of novel therapeutical targets and mechanisms which are targeting the peptidergic sensory nerves and inhibiting their pathological activation.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The university seeks research cooperation, partners for common development and out-licensing partners from all countries.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Hungarian

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos
06001014 Neurología, investigación cerebral